estradiol-drospirenone combination: consists of 17beta-estradiol and drospirenone; used to treat menopause [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 9874151 |
| SCHEMBL ID | 8459807 |
| MeSH ID | M0491520 |
| Synonym |
|---|
| estradiol-drospirenone combination |
| drospirenone and estradiol |
| eliq |
| 350818-73-4 |
| bay 86-4891 |
| estradiol / drospirenone |
| drospirenone / estradiol |
| SCHEMBL8459807 |
| DTXSID30188582 |
| (1r,2r,4r,10r,11s,14s,15s,16s,18s,19s)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (39.13%) | 5.53% |
| Reviews | 8 (34.78%) | 6.00% |
| Case Studies | 1 (4.35%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (21.74%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| spironolactone | 3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester | aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| aldosterone | 11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde | human metabolite; mouse metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| drospirenone | 3-oxo-Delta(4) steroid; steroid lactone | aldosterone antagonist; contraceptive drug; progestin | 2004 | 2015 | 16.1 | high | 1 | 0 | 0 | 5 | 2 | 0 | |
| tibolone | 17beta-hydroxy steroid; terminal acetylenic compound | bone density conservation agent; hormone agonist | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| atrial natriuretic factor | polypeptide | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Angina Pectoris | 0 | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Angor Pectoris | 0 | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Bilateral Nasal Obstruction | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Blood Pressure, High | 0 | 2005 | 2020 | 14.2 | low | 0 | 0 | 0 | 3 | 1 | 0 | |
| Body Weight | 0 | 2005 | 2013 | 16.0 | low | 1 | 0 | 0 | 2 | 1 | 0 | |
| Bone Loss, Perimenopausal | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cardiovascular Diseases | 0 | 2007 | 2015 | 13.0 | low | 2 | 0 | 0 | 1 | 2 | 0 | |
| Central Nervous System Origin Vertigo | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Dizziness | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Dizzyness | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Dry Eye | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Dry Eye Syndromes | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Eye Diseases | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Eye Disorders | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Glucose Intolerance | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Hemorrhage, Uterine | 0 | 2013 | 2015 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Hot Flashes | 0 | 2007 | 2015 | 13.0 | low | 1 | 0 | 0 | 1 | 2 | 0 | |
| Hypertension | 0 | 2005 | 2020 | 14.2 | low | 0 | 0 | 0 | 3 | 1 | 0 | |
| Impaired Glucose Tolerance | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Intraocular Pressure | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Menopause | 0 | 2004 | 2007 | 18.3 | low | 0 | 0 | 0 | 3 | 0 | 0 | |
| Nasal Obstruction | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Osteoporosis, Postmenopausal | 0 | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Polycystic Ovarian Syndrome | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Polycystic Ovary Syndrome | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Premenstrual Syndrome | 0 | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Premenstrual Tension | 0 | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Uterine Hemorrhage | 0 | 2013 | 2015 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Vaginal Diseases | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Vertigo | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| [Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties]. Revue medicale de Liege, , Volume: 59, Issue:3 | 2004 |
| Article | Year |
|---|---|
| 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes. Climacteric : the journal of the International Menopause Society, , Volume: 18, Issue:4 | 2015 |
| Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric : the journal of the International Menopause Society, , Volume: 8 Suppl 3 | 2005 |